The tau antibodies used herein were generated against Tau386-408[P-Ser396, 404], a prominent pathological epitope in AD and other tauopathies, and have been characterized previously to some extent, showing the efficacy of the 4E6 antibody and relative lack thereof for the 6B2 antibody (7, 12, 14, 16, 19, 22, 23, 27). Here, MAPT is linked to Alzheimer disease.